This study sought to validate 18FLT‐PET in an expanded cohort of pulmonary arterial hypertension patients in comparison to matched healthy controls and unaffected bone morphogenetic protein receptor type 2 mutation carriers. Here, BMPR2 is linked to pulmonary arterial hypertension.